Patents Examined by Alana Harris Dent
  • Patent number: 11219672
    Abstract: A cancer therapeutic agent according to an embodiment of the present invention contains, as active ingredients, IL-18 and one or more antibodies selected from the group consisting of an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-PD-L2 antibody, an anti-CTLA-4 antibody, an anti-CD25 antibody, an anti-CD33 antibody, and an anti-CD52 antibody.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: January 11, 2022
    Assignees: Medical Research and Development Corporation, Foundation for Biomedical Research and Innovation
    Inventors: Haruki Okamura, Kyosuke Yamanishi, Wen Li
  • Patent number: 11193944
    Abstract: The present invention relates to a method for the accurate, rapid and sensitive detection of breast or ovarian cancers from body fluid samples of a mammalian subject and related assay, kits and peptides suitable for such a method.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: December 7, 2021
    Assignee: BARD1 LIFE SCIENCES LIMITED
    Inventors: Solomzi Makohliso, Irmgard Irminger-Finger, Fernando Herrera
  • Patent number: 11186633
    Abstract: Provided is a rabbit monoclonal antibody to acetylated mouse BubR1 and a preparation method therefor and, more particularly, provides the use of the monoclonal antibody in a method for measuring the activity of cell division checkpoints on the basis of a degree of acetylation of BubR1, a method for detecting a tumor disease on the basis of aberrant cell division, a method for diagnosing cancer, a method for screening anti-cancer agents, or a method for regulating a cell division cycle.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: November 30, 2021
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Hyunsook Lee, Mi-Sun Kwon, Inai Park, Hyeon-Jong Kim
  • Patent number: 11179449
    Abstract: The invention relates to combinations of peptides carrying T-cell epitopes of the antigen preprocalcitonin, presented by the MHC. These peptides can be used in anti-tumour immunotherapy.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: November 23, 2021
    Assignees: Institut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale, Université Paris-Saclay
    Inventors: Fathia Mami-Chouaib, Aurélie Durgeau
  • Patent number: 11130789
    Abstract: Early detection of tumors is a major determinant of survival of patients suffering from tumors, including bladder tumors. Members of the BTM or UBTM family can be highly and consistently accumulated in bladder tumor tissue and other tumor tissue, and/or can be accumulated in urine of patients, and thus are markers for bladder and other types of cancer. In certain embodiments, BTMs or UBTMs can accumulate in the urine, and detection of UBTM family members can be an effective diagnostic approach. In some embodiments, quantitative PCR methods have advantages over microarray methods. In other embodiments, detection and quantification of a plurality of BTMs or UBTMs can increase the sensitivity and specificity of detection of bladder cancer, and therefore provides methods for determining the stage and type of bladder cancer. Kits provide easy, convenient ways for carrying out the methods of this invention.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: September 28, 2021
    Assignee: Pacific Edge Limited
    Inventors: Parry John Guilford, Natalie Jane Kerr, Robert Craig Pollock
  • Patent number: 11117951
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: September 14, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11117957
    Abstract: The present invention relates to the use of BAG3 antibodies as a medicament, in particular for use in the treatment of pancreatic tumours or other pathologies of an immune, inflammatory, neoplastic and/or degenerative nature.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: September 14, 2021
    Assignee: BIOUNIVERSA S.R.L.
    Inventor: Maria Caterina Turco
  • Patent number: 11098103
    Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: August 24, 2021
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Brennan, David Bellovin, David Busha, Barbara Sennino
  • Patent number: 11073521
    Abstract: A method of obtaining a population of cells enriched in human polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) comprises isolating from a cell suspension those cells which express LOX-1 to provide a population of cells enriched with PMN-MDSCs. A method of monitoring the population of LOX-1+ cells in a cell-containing biological sample is useful for determining the efficacy of treatment or the metastasis or increasing progression of cancer. Other cell isolation and diagnostic methods are also described.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: July 27, 2021
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Dmitry I. Gabrilovich, Thomas C. Condamine
  • Patent number: 11065316
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: July 20, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11058744
    Abstract: The present invention relates to a composition for treating prostate cancer and, more specifically, to a composition for treating prostate cancer, which contains a peptide derived from telomerase and is effective in inhibiting growth and metastasis of prostate cancer cells. In addition, the present invention provides a composition and method for treating prostate cancer, wherein, when prostate cancer is treated, docetaxel and the peptide derived from telomerase are co-administered, thereby having a synergetic therapeutic effect compared with administration alone. Particularly, the present invention provides a treatment method useful for patients who do not have a sufficient anticancer effect merely through administration of docetaxel alone and patients who have hormone resistance.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: July 13, 2021
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 11033622
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: June 15, 2021
    Assignee: Leidos, Inc.
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, Timothy W. Phares, James Pannucci
  • Patent number: 11000578
    Abstract: Provided herein is technology relating to cancer treatment and prevention and particularly, but not exclusively, to compositions and methods related to therapies for prostate cancer.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: May 11, 2021
    Assignee: Madison Vaccines Inc.
    Inventors: Doug McNeel, Richard Lesniewski
  • Patent number: 10987413
    Abstract: The present invention relates to novel tumor-associated antigens, which elicit independently from a presentation via MHC a CD8-positive T-cell response. GM-CSF-Receptor alpha chain (CSF2RA) and Tyrosinase-related protein 2 (TRP-2) were found to be targets of CD8-positive T-cell clones which could detect the proteins on the surface of HLA I negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Furthermore provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: April 27, 2021
    Assignee: BioNTech RNA Pharmaceuticals GmbH
    Inventors: Dirk Schadendorf, Annette Paschen, Silke Lübcke, Martina Fatho, Daniela Eberts, Hakim Echchannaoui, Volker Lennerz, Catherine Woelfel, Thomas Woelfel
  • Patent number: 10980797
    Abstract: This invention provides a method that combines a checkpoint inhibitor and a glucocorticoid receptor modulator to treat cancer, e.g., a checkpoint inhibitor sensitive cancer.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: April 20, 2021
    Assignee: Corcept Therapeutics Incorporated
    Inventor: Hazel Hunt
  • Patent number: 10976318
    Abstract: The present invention relates to the use as a biomarker of the active form of a human caspase protein, preferably the human caspase-4 or caspase-1, or of the active form of the protein encoded by an orthologue gene of the human caspase protein, preferably by an orthologue gene of the human caspase-4, for example the murine caspase-11 protein, in a method of diagnosis and/or prognosis and/or of monitoring the progression of a tumor, particularly lung cancer.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: April 13, 2021
    Assignee: IMMUNEPHARMA S.R.L.
    Inventors: Aldo Pinto, Rita Patrizia Aquino, Rosalinda Sorrentino, Michela Terlizzi
  • Patent number: 10948493
    Abstract: Antibodies, compositions, systems, and methods for detecting C4.4a, for example immunohistochemistry methods for detecting C4.4a using a C4.4a antibody. The antibody may be obtained by immunizing a host with a C4.4a protein such as a peptide downstream of the signal peptide. The antibodies may be adapted to detect the uPAR-like domain 1 and uPAR-like domain 2. Also featured are methods for diagnosing C4.4a-associated tumors using C4.4a antibodies disclosed herein.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: March 16, 2021
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Fernando Jose Rebelo do Couto, Zhiming Liao, Yifei Zhu
  • Patent number: 10934339
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: March 2, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10907209
    Abstract: The invention relates to modulating the SIRP?-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRP? polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: February 2, 2021
    Assignees: UNIVERSITY HEALTH NETWORK, THE HOSPITAL FOR SICK CHILDREN
    Inventors: Jean C. Y. Wang, John Dick, Jayne Danska, Liqing Jin, Alexandre Theocharides, Sujeetha Rajakumar
  • Patent number: 10906954
    Abstract: CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRP?/CD47 axis. The agent is a human SIRP? fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain from variant 2 of human SIRP?, and an Fc having effector function. The IgV domain binds human CD47 with an affinity that is at least five fold greater than the affinity of the entire extracellular region of human SIRP?. The fusion protein is at least 5 fold more potent than a counterpart lacking effector function.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: February 2, 2021
    Assignee: TRILLIUM THERAPEUTICS INC.
    Inventors: Robert Adam Uger, Penka Slavtcheva Slavova-Petrova, Xinli Pang